ClearPoint Neuro director sells shares for taxes

ClearPoint Neuro director Timothy T. Richards sold 5,415 shares of Common Stock.

Accepted by SEC EDGAR 06/02/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ClearPoint Neuro director Timothy T. Richards sold 5,415 shares of Common Stock. The open-market sale on June 1, 2026 was executed at a weighted average price of $12.17 per share, with individual trades ranging from $12.04 to $12.47 per share.

According to the filing, the sale was made to cover the tax liability associated with the vesting of 12,417 restricted stock units on May 19, 2026. After this transaction, Richards directly holds 87,198 shares of ClearPoint Neuro common stock.

Insider Trade Summary

Net Seller: 5,415 shares

Net Sell 1 txn

Insider Richards Timothy T.

Role Director

Sold 5,415 shs ($66K)

Share of Position Sold 5.8%

Type	Security	Shares	Price	Value
Sale	Common Stock	5,415	$12.17	$66K

Holdings After Transaction: Common Stock — 87,198 shares (Direct)

Holdings Before and After: Common Stock, 92,613 to 87,198 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. This sale of shares was made to cover the tax liability incident to the vesting of 12,417 shares on May 19, 2026 under a restricted stock unit granted to the director on May 22, 2025.
2. F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $12.04 to $12.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Key Figures

Shares sold: 5,415 shares Weighted average sale price: $12.17 per share Post-transaction holdings: 87,198 shares +2 more

5 metrics

Shares sold 5,415 shares Open-market sale on June 1, 2026

Weighted average sale price $12.17 per share Common Stock sale

Post-transaction holdings 87,198 shares Director’s direct ownership after sale

RSUs vested 12,417 shares Restricted stock units vested on May 19, 2026

Sale price range $12.04–$12.47 per share Range of trade prices in sale

Key Terms

restricted stock unit, weighted average sales price per share, open-market sale, tax liability

4 terms

restricted stock unit financial

"the vesting of 12,417 shares on May 19, 2026 under a restricted stock unit granted"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

weighted average sales price per share financial

"Represents a weighted average sales price per share. The shares were sold at prices"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax liability financial

"sale of shares was made to cover the tax liability incident to the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ClearPoint Neuro (CLPT) director Timothy T. Richards do in this Form 4?

Director Timothy T. Richards sold 5,415 shares of ClearPoint Neuro common stock. The shares were sold in the open market to address tax obligations tied to a recent restricted stock unit vesting.

How many ClearPoint Neuro (CLPT) shares did the director sell and at what price?

Richards sold 5,415 shares of ClearPoint Neuro common stock. The weighted average sale price was $12.17 per share, with individual trade prices ranging between $12.04 and $12.47 per share.

Why did the ClearPoint Neuro (CLPT) director sell shares in this transaction?

The sale was made to cover the tax liability from vesting restricted stock units. Specifically, 12,417 restricted stock units vested on May 19, 2026, and the share sale helped satisfy the related tax obligations.

How many ClearPoint Neuro (CLPT) shares does the director hold after the sale?

Following the sale, Richards directly holds 87,198 shares of ClearPoint Neuro common stock. This figure reflects his remaining direct ownership after disposing of 5,415 shares in the reported transaction.

What type of transaction is reported for ClearPoint Neuro (CLPT) in this Form 4?

The filing reports an open-market sale of common stock by a director. It is categorized as a non-derivative transaction with the code “S,” indicating a sale in the open market or a private transaction.

What equity award triggered the tax-related sale for ClearPoint Neuro (CLPT)?

The tax-related sale was linked to a restricted stock unit award. A total of 12,417 restricted stock units granted on May 22, 2025, vested on May 19, 2026, creating the tax liability that the share sale helped cover.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Richards Timothy T.

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		5,415	D	$12.17(2)	87,198	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale of shares was made to cover the tax liability incident to the vesting of 12,417 shares on May 19, 2026 under a restricted stock unit granted to the director on May 22, 2025.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $12.04 to $12.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

	/s/ Danilo D'Alessandro, by Power of Attorney for Timothy T. Richards	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)